Advanced in Lung Nodules

Dr. Lecia Van Dam Sequist

Oncology
Massachusetts General Hospital
The General Hospital Corporation
40 2nd Ave, 
Waltham, MA 
Offers Telehealth
Advanced in Lung Nodules
Massachusetts General Hospital
The General Hospital Corporation
40 2nd Ave, 
Waltham, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Lecia Van Dam Sequist is an Oncologist in Waltham, Massachusetts. Dr. Van Dam Sequist is rated as an Advanced provider by MediFind in the treatment of Lung Nodules. Her top areas of expertise are EGFR Positive Lung Cancer, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and Tissue Biopsy.

Her clinical research consists of co-authoring 265 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles in the study of Lung Nodules.

Graduate Institution
Harvard Medical School, 1995 - 1999
Residency
Brigham and Women's Hospital, 1999 - 2002
Specialties
Oncology
Licenses
Internal Medicine in MA
Board Certifications
Medical Oncology
Fellowships
Brigham and Women's and Dana Farber combined program, 2002 - 2005
Hospital Affiliations
Newton-Wellesley Hospital
Massachusetts General Hospital
Brigham And Women's Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

THE GENERAL HOSPITAL CORPORATION
40 2nd Ave, Waltham, MA 02451
Call: 781-487-2900
Other Locations
THE GENERAL HOSPITAL CORPORATION
55 Fruit St, Boston, MA 02114
Call: 617-726-2000
THE GENERAL HOSPITAL CORPORATION
2014 Washington St, Newton, MA 02462
Call: 617-219-1200

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Phase 1/2 Study of TAS-120 in Patients With Advanced Solid Tumors Harboring FGF/FGFR Aberrations
Phase 1/2 Study of TAS-120 in Patients With Advanced Solid Tumors Harboring FGF/FGFR Aberrations
Enrollment Status: Completed
Publish Date: March 27, 2025
Intervention Type: Drug
Study Drug: TAS-120
Study Phase: Phase 1/Phase 2
A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies
A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies
Enrollment Status: Completed
Publish Date: December 11, 2024
Intervention Type: Drug
Study Drug: EGF816
Study Phase: Phase 1/Phase 2
Afatinib Sequenced With Concurrent Chemotherapy and Radiation in EGFR-Mutant Non-Small Cell Lung Tumors: The ASCENT Trial
Afatinib Sequenced With Concurrent Chemotherapy and Radiation in EGFR-Mutant Non-Small Cell Lung Tumors: The ASCENT Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 20, 2024
Intervention Type: Procedure, Drug, Radiation
Study Drugs: Afatinib, Cisplatin, Pemetrexed
Study Phase: Phase 2
A Phase Ib/II, Multicenter, Open-label Study of EGF816 in Combination With INC280 in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer.
A Phase Ib/II, Multicenter, Open-label Study of EGF816 in Combination With INC280 in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer.
Enrollment Status: Terminated
Publish Date: June 18, 2023
Intervention Type: Drug
Study Drugs: Capmatinib, Nazartinib
Study Phase: Phase 1/Phase 2
Randomized Phase II Study Comparing Concise Versus Prolonged Afatinib as Adjuvant Therapy for Patients With Resected Stage I-III NSCLC With EGFR Mutation
Randomized Phase II Study Comparing Concise Versus Prolonged Afatinib as Adjuvant Therapy for Patients With Resected Stage I-III NSCLC With EGFR Mutation
Enrollment Status: Unknown
Publish Date: July 07, 2020
Intervention Type: Drug
Study Drug: Afatinib
Study Phase: Phase 2
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Enrollment Status: Completed
Publish Date: October 04, 2019
Intervention Type: Drug
Study Phase: Phase 1
Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Enrollment Status: Completed
Publish Date: April 10, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

265 Total Publications

Lung Cancer Screening Saves Lives, but Could Save So Many More.
Lung Cancer Screening Saves Lives, but Could Save So Many More.
Journal: JAMA
Published: November 19, 2025
View All 265 Publications
Similar Doctors
Distinguished in Lung Nodules
Dr. Justin F. Gainor
Oncology | Hematology
Distinguished in Lung Nodules
Dr. Justin F. Gainor
Oncology | Hematology

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
 (10.3 miles away)
617-726-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Justin Gainor is an Oncologist and a Hematologist in Boston, Massachusetts. Dr. Gainor is rated as an Elite provider by MediFind in the treatment of Lung Nodules. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and EGFR Positive Lung Cancer. Dr. Gainor is currently accepting new patients.

Advanced in Lung Nodules
Dr. Jennifer S. Temel
Oncology
Advanced in Lung Nodules
Dr. Jennifer S. Temel
Oncology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (10.3 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jennifer Temel is an Oncologist in Boston, Massachusetts. Dr. Temel is rated as an Elite provider by MediFind in the treatment of Lung Nodules. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Bone Marrow Transplant, and Gastrostomy.

Ibiayi Dagogo-Jack
Advanced in Lung Nodules
Dr. Ibiayi Dagogo-Jack
Hematology Oncology | Oncology | Hematology
Advanced in Lung Nodules
Dr. Ibiayi Dagogo-Jack
Hematology Oncology | Oncology | Hematology

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
 (10.3 miles away)
617-726-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ibiayi Dagogo-Jack is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Dagogo-Jack is rated as an Elite provider by MediFind in the treatment of Lung Nodules. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Lung Adenocarcinoma, and Tissue Biopsy. Dr. Dagogo-Jack is currently accepting new patients.

VIEW MORE LUNG NODULES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Van Dam Sequist's expertise for a condition
ConditionClose
  • Elite
  • EGFR Positive Lung Cancer
    Dr. Van Dam Sequist is
    Elite
    . Learn about EGFR Positive Lung Cancer.
    See more EGFR Positive Lung Cancer experts
  • Lung Adenocarcinoma
    Dr. Van Dam Sequist is
    Elite
    . Learn about Lung Adenocarcinoma.
    See more Lung Adenocarcinoma experts
  • Lung Cancer
    Dr. Van Dam Sequist is
    Elite
    . Learn about Lung Cancer.
    See more Lung Cancer experts
  • Non-Small Cell Lung Cancer (NSCLC)
    Dr. Van Dam Sequist is
    Elite
    . Learn about Non-Small Cell Lung Cancer (NSCLC).
    See more Non-Small Cell Lung Cancer (NSCLC) experts
  • Small Cell Lung Cancer (SCLC)
    Dr. Van Dam Sequist is
    Elite
    . Learn about Small Cell Lung Cancer (SCLC).
    See more Small Cell Lung Cancer (SCLC) experts
  • Distinguished
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Van Dam Sequist is
    Distinguished
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • Large-Cell Lung Carcinoma
    Dr. Van Dam Sequist is
    Distinguished
    . Learn about Large-Cell Lung Carcinoma.
    See more Large-Cell Lung Carcinoma experts
  • Pleuropulmonary Blastoma
    Dr. Van Dam Sequist is
    Distinguished
    . Learn about Pleuropulmonary Blastoma.
    See more Pleuropulmonary Blastoma experts
  • Squamous Cell Lung Carcinoma
    Dr. Van Dam Sequist is
    Distinguished
    . Learn about Squamous Cell Lung Carcinoma.
    See more Squamous Cell Lung Carcinoma experts
  • Tissue Biopsy
    Dr. Van Dam Sequist is
    Distinguished
    . Learn about Tissue Biopsy.
    See more Tissue Biopsy experts
  • Advanced
  • Lung Nodules
    Dr. Van Dam Sequist is
    Advanced
    . Learn about Lung Nodules.
    See more Lung Nodules experts
  • Experienced
  • Anal Cancer
    Dr. Van Dam Sequist is
    Experienced
    . Learn about Anal Cancer.
    See more Anal Cancer experts
  • Bone Tumor
    Dr. Van Dam Sequist is
    Experienced
    . Learn about Bone Tumor.
    See more Bone Tumor experts
  • Brain Tumor
    Dr. Van Dam Sequist is
    Experienced
    . Learn about Brain Tumor.
    See more Brain Tumor experts
  • Breast Cancer
    Dr. Van Dam Sequist is
    Experienced
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Familial Pancreatic Cancer
    Dr. Van Dam Sequist is
    Experienced
    . Learn about Familial Pancreatic Cancer.
    See more Familial Pancreatic Cancer experts
  • Melanoma
    Dr. Van Dam Sequist is
    Experienced
    . Learn about Melanoma.
    See more Melanoma experts
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.